These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21494716)

  • 1. A robust method to quantify low molecular weight contaminants in heparin: detection of tris(2-n-butoxyethyl) phosphate.
    Sassaki GL; Riter DS; Santana Filho AP; Guerrini M; Lima MA; Cosentino C; Souza LM; Cipriani TR; Rudd TR; Nader HB; Yates EA; Gorin PA; Torri G; Iacomini M
    Analyst; 2011 Jun; 136(11):2330-8. PubMed ID: 21494716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of oversulfated chondroitin sulfate and dermatan sulfate impurities in heparin by capillary electrophoresis.
    Somsen GW; Tak YH; Toraño JS; Jongen PM; de Jong GJ
    J Chromatogr A; 2009 May; 1216(18):4107-12. PubMed ID: 19272607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining (1)H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants.
    Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
    J Pharm Biomed Anal; 2011 Apr; 54(5):1020-9. PubMed ID: 21215547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-sensitivity visualisation of contaminants in heparin samples by spectral filtering of 1H NMR spectra.
    Rudd TR; Gaudesi D; Lima MA; Skidmore MA; Mulloy B; Torri G; Nader HB; Guerrini M; Yates EA
    Analyst; 2011 Apr; 136(7):1390-8. PubMed ID: 21279244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of oversulfated chondroitin sulfate in low molecular weight and unfractioned heparins diffusion ordered nuclear magnetic resonance spectroscopy method.
    Sitkowski J; Bednarek E; Bocian W; Kozerski L
    J Med Chem; 2008 Dec; 51(24):7663-5. PubMed ID: 19055319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orthogonal analytical approaches to detect potential contaminants in heparin.
    Guerrini M; Zhang Z; Shriver Z; Naggi A; Masuko S; Langer R; Casu B; Linhardt RJ; Torri G; Sasisekharan R
    Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16956-61. PubMed ID: 19805108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin.
    Viskov C; Bouley E; Hubert P; Martinez C; Herman F; Jeske W; Hoppensteadt D; Walenga JM; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(4):395-401. PubMed ID: 19617248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy.
    Beyer T; Diehl B; Randel G; Humpfer E; Schäfer H; Spraul M; Schollmayer C; Holzgrabe U
    J Pharm Biomed Anal; 2008 Sep; 48(1):13-9. PubMed ID: 18678460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMR of heparin API: investigation of unidentified signals in the USP-specified range of 2.12-3.00 ppm.
    Lee SE; Chess EK; Rabinow B; Ray GJ; Szabo CM; Melnick B; Miller RL; Nair LM; Moore EG
    Anal Bioanal Chem; 2011 Jan; 399(2):651-62. PubMed ID: 20949261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin sodium compliance to USP monograph: structural elucidation of an atypical 2.18 ppm NMR signal.
    Mourier PA; Guichard OY; Herman F; Viskov C
    J Pharm Biomed Anal; 2012; 67-68():169-74. PubMed ID: 22579602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assay of possible economically motivated additives or native impurities levels in heparin by 1H NMR, SAX-HPLC, and anticoagulation time approaches.
    Keire DA; Mans DJ; Ye H; Kolinski RE; Buhse LF
    J Pharm Biomed Anal; 2010 Sep; 52(5):656-64. PubMed ID: 20233649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Class modeling analysis of heparin 1H NMR spectral data using the soft independent modeling of class analogy and unequal class modeling techniques.
    Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
    Anal Chem; 2011 Feb; 83(3):1030-9. PubMed ID: 21192734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of crude heparin by (1)H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate.
    Keire DA; Trehy ML; Reepmeyer JC; Kolinski RE; Ye W; Dunn J; Westenberger BJ; Buhse LF
    J Pharm Biomed Anal; 2010 Mar; 51(4):921-6. PubMed ID: 19959313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin sodium compliance to the new proposed USP monograph: elucidation of a minor structural modification responsible for a process dependent 2.10 ppm NMR signal.
    Mourier PA; Guichard OY; Herman F; Viskov C
    J Pharm Biomed Anal; 2011 Jan; 54(2):337-44. PubMed ID: 20934294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assessment of polydispersed species in unfractionated and low molecular weight heparins by diffusion ordered nuclear magnetic resonance spectroscopy method.
    Bednarek E; Sitkowski J; Bocian W; Mulloy B; Kozerski L
    J Pharm Biomed Anal; 2010 Nov; 53(3):302-8. PubMed ID: 20417048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative capillary electrophoresis determination of oversulfated chondroitin sulfate as a contaminant in heparin preparations.
    Volpi N; Maccari F; Linhardt RJ
    Anal Biochem; 2009 May; 388(1):140-5. PubMed ID: 19232311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved impurity fingerprinting of heparin by high resolution (1)H NMR spectroscopy.
    Bigler P; Brenneisen R
    J Pharm Biomed Anal; 2009 May; 49(4):1060-4. PubMed ID: 19211212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (1)H NMR signal at 2.10 ppm in the spectrum of KMnO(4)-bleached heparin sodium: identification of the chemical origin using an NMR-only approach.
    Kellenbach E; Sanders K; Michiels PJ; Girard FC
    Anal Bioanal Chem; 2011 Jan; 399(2):621-8. PubMed ID: 21069304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of heparin samples that contain impurities or contaminants by chemometric pattern recognition analysis of proton NMR spectral data.
    Zang Q; Keire DA; Buhse LF; Wood RD; Mital DP; Haque S; Srinivasan S; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
    Anal Bioanal Chem; 2011 Aug; 401(3):939-55. PubMed ID: 21678118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of currently marketed heparin products: key tests for quality assurance.
    Keire DA; Ye H; Trehy ML; Ye W; Kolinski RE; Westenberger BJ; Buhse LF; Nasr M; Al-Hakim A
    Anal Bioanal Chem; 2011 Jan; 399(2):581-91. PubMed ID: 20680615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.